

Joshua N Gustine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/821837/publications.pdf>

Version: 2024-02-01

34
papers

1,700
citations

394421

19
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

1829
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunopathology of Hyperinflammation in COVID-19. <i>American Journal of Pathology</i> , 2021, 191, 4-17.	3.8	372
2	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2755-2761.	1.6	142
3	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. <i>Blood</i> , 2017, 129, 2519-2525.	1.4	115
4	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 1198-1208.	1.6	103
5	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	1.6	98
6	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. <i>Blood</i> , 2016, 128, 827-838.	1.4	91
7	MYD88 wild-type Waldenström Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. <i>British Journal of Haematology</i> , 2018, 180, 374-380.	2.5	83
8	CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 356-363.	2.5	73
9	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. <i>Blood Advances</i> , 2018, 2, 2937-2946.	5.2	72
10	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 177, 717-725.	2.5	58
11	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2018, 24, 3247-3252.	7.0	57
12	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1032-1035.	4.1	53
13	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2022, 36, 532-539.	7.2	50
14	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
15	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 181, 77-85.	2.5	41
16	Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. <i>Leukemia and Lymphoma</i> , 2017, 58, 1002-1004.	1.3	31
17	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. <i>Blood Advances</i> , 2019, 3, 2800-2803.	5.2	27
18	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenström Macroglobulinemia (WMCTG 09-214). <i>Clinical Cancer Research</i> , 2017, 23, 2400-2404.	7.0	23

#	ARTICLE	IF	CITATIONS
19	To select or not to select? The role of Bâ€cell selection in determining the <i><sc>MYD</sc>88</i> mutation status in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2017, 176, 822-824.	2.5	22
20	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 1011-1014.	2.5	19
21	Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic nextâ€generation sequencing in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733.	2.5	16
22	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2021, 5, e624.	2.7	15
23	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With WaldenstrÃ¶m Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363.	2.7	12
24	<sc>CXCR4</sc> mutational status does not impact outcomes in patients with <sc>W</sc>aldenstrÃ¶m macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98.	4.1	12
25	Response and survival predictors in a cohort of 319 patients with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	5.2	12
26	Predictors of hematologic response and survival with stem cell transplantation in <sc>AL</sc> amyloidosis: A 25â€year longitudinal study. American Journal of Hematology, 2022, 97, 1189-1199.	4.1	12
27	Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	3.5	11
28	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	1.3	9
29	Partial response or better at sixâ€months is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	2.5	8
30	Cellâ€free <sc>DNA</sc> analysis for detection of <sc><i>MYD88</i>^{L265P}</sc> and <sc><i>CXCR4</i>^{S338X}</sc> mutations in <sc>W</sc>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	4.1	8
31	Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium. Current Microbiology, 2019, 76, 398-409.	2.2	5
32	Long survival in patients with WaldenstrÃ¶m macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802.	2.5	4
33	Comparing apples to oranges: A commentary on the <sc>M</sc>ayo study of <sc>MYD</sc>88 significance in <sc>W</sc>aldenstrom's macroglobulinemia.. American Journal of Hematology, 2018, 93, E69-E71.	4.1	1
34	Fitting mSMART Into the Current Clinical Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2018, 4, 744.	7.1	0